US equities
|
TSLA
$391.62
▲+5.21%
MU
$903.70
▲+2.98%
META
$630.56
▼-1.88%
NVDA
$216.00
▲+2.39%
AAPL
$343.91
▼-1.10%
SPCX
$146.90
▼-0.40%
MSFT
$532.60
▲+1.54%
AMD
$531.28
▲+2.80%
TSLA
$391.62
▲+5.21%
MU
$903.70
▲+2.98%
META
$630.56
▼-1.88%
NVDA
$216.00
▲+2.39%
AAPL
$343.91
▼-1.10%
SPCX
$146.90
▼-0.40%
MSFT
$532.60
▲+1.54%
AMD
$531.28
▲+2.80%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
InMed Pharmaceuticals Inc. - Common Shares
(NQ:
INM
)
1.590
+0.150 (+10.42%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about InMed Pharmaceuticals Inc. - Common Shares
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expanding Portfolio, Presence in Growing Rare Cannabinoid Market
March 03, 2022
Via
CannabisNewsWire
Topics
Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expanding Portfolio, Presence in Growing Rare Cannabinoid Market
March 03, 2022
Via
Investor Brand Network
Topics
Supply Chain
InMed Pharmaceuticals Inc. (NASDAQ: INM) and BayMedica Rare Cannabinoids to Enter Market Q1 2022; Leveraging on Fast-Growing Global Health and Wellness Market
March 02, 2022
Via
CannabisNewsWire
Stocks That Hit 52-Week Lows On Wednesday
↗
March 02, 2022
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by...
Via
Benzinga
InMed Pharmaceuticals Inc. (NASDAQ: INM) and BayMedica Rare Cannabinoids to Enter Market Q1 2022; Leveraging on Fast-Growing Global Health and Wellness Market
March 02, 2022
Via
Investor Brand Network
InMed's Evolution To Commercial Sales Featured In Research Report
↗
February 17, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice....
Via
Benzinga
InMed’s (NASDAQ: INM) Evolution to Commercial Sales Featured in Research Report
February 17, 2022
Via
Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Evolution to Commercial Sales to Health and Wellness Market Featured in Research Report
February 16, 2022
Via
Investor Brand Network
InMed Names BayMedica VP Of Sales, Releases Q2 2022 Report
↗
February 16, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a...
Via
Benzinga
InMed (NASDAQ: INM) Names BayMedica VP of Sales, Releases Q2 2022 Report
February 16, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Supply Chain
InMed Pharmaceuticals (INM): Generating Commercial Sales of CBC and CBT
February 16, 2022
LONDON, UK / ACCESSWIRE / February 16, 2022 / InMed Pharmaceuticals' (INM's) Q222 financial results reflect its evolution from a pure-play biotech firm to one with commercial sales to the health and...
From
Edison Investment Research Limited
Via
AccessWire
InMed Positioned To Offer Rare Cannabinoid Manufacturing Technologies
↗
February 15, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice....
Via
Benzinga
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names BayMedica VP of Sales, Releases Q2 2022 Report
February 15, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Supply Chain
InMed (NASDAQ: INM) Positioned to Offer Rare Cannabinoid Manufacturing Technologies
February 15, 2022
Via
Investor Brand Network
Topics
Cannabis
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) in Unique Position to Offer Full Slate of Rare Cannabinoid Manufacturing Technologies
February 14, 2022
Via
Investor Brand Network
Topics
Cannabis
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) in Unique Position to Offer Full Slate of Rare Cannabinoid Manufacturing Technologies
February 14, 2022
Via
CannabisNewsWire
Topics
Cannabis
InMed Pharmaceuticals To Release Q2 Financial Report, Update
↗
February 11, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a...
Via
Benzinga
InMed Pharmaceuticals (NASDAQ: INM) to Release Q2 Financial Report, Update
February 11, 2022
Via
Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Release Q2 Financial Report, Business Update
February 10, 2022
Via
Investor Brand Network
InMed Pharmaceuticals Strengthens Leading Role In Rare Cannabinoid Market
↗
February 04, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Cannabicitran is the first of four new rare cannabinoids InMed...
Via
Benzinga
InMed Pharmaceuticals (NASDAQ: INM) Strengthens Leading Role in Rare Cannabinoid Market
February 04, 2022
Via
Investor Brand Network
InMed Pharmaceuticals Inc. (NASDAQ: INM) Strengthens Leading Role in Rare Cannabinoid Market Following New Product Launch, Key Acquisition
February 03, 2022
Via
Investor Brand Network
InMed Pharmaceuticals Defining Value Of Rare Cannabinoids In Pharma Space
↗
February 03, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
InMed Pharmaceuticals (NASDAQ: INM) Defining Value of Rare Cannabinoids in Pharma Space
February 03, 2022
Via
Investor Brand Network
Topics
Cannabis
CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Blazing Trail in Defining Value of Rare Cannabinoids in Pharmaceutical Space
February 02, 2022
Via
Investor Brand Network
Topics
Cannabis
InMed (NASDAQ: INM) Gains Potential to Synthetically Produce Rare Cannabinoids at Scale
February 02, 2022
Via
Investor Brand Network
Topics
Cannabis
InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Recent Access of Manufacturing Technologies Now Give It the Potential to Synthetically Produce Rare Cannabinoids at Large Scale, a Unique and Coveted Position in the Rapidly Developing Rare Cannabinoid Space
February 01, 2022
Via
Investor Brand Network
Topics
Cannabis
InMed Pharmaceuticals (NASDAQ: INM) Leveraging Growing Cannabinoid-Based Pharma Market
January 27, 2022
Via
Investor Brand Network
Topics
Cannabis
InMed Pharmaceuticals Inc. (NASDAQ: INM) Leveraging on the Growing Cannabinoid-Based Pharmaceuticals Market
January 26, 2022
Via
Investor Brand Network
Topics
Cannabis
InMed Pharmaceuticals Inc. (NASDAQ: INM) Leveraging on the Growing Cannabinoid-Based Pharmaceuticals Market
January 26, 2022
Via
CannabisNewsWire
Topics
Cannabis
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
